Risk factors of emergency care and admissions in COPD patients with high consumption of health resources

Respiratory Medicine

Volumn 98, Issue 4, 2004, Pages 318-329

  Soler, Juan José ^a   Sánchez, Lourdes ^a   Román, Pilar ^a   Martínez, Miguel Ángel ^a   Perpiñá, Miguel ^b  

^a HOSPITAL GENERAL DE REQUENA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Acute disease; Chronic obstructive pulmonary disease; Health resources; Hospitalization

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DIURETIC AGENT; FLUTICASONE; FORMOTEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; OXYGEN; SALBUTAMOL; SALMETEROL; THEOPHYLLINE;

ADULT; AGED; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; ARTICLE; BREATHING MUSCLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; EMERGENCY WARD; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG PRESSURE; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL PARAMETERS; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; SMOKING HABIT; SOCIOECONOMICS; SPIROMETRY;

EID: 11144356852     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.04.001     Document Type: Article

References (49)

1. Sobradillo V, Miratvilles M, Gabriel R, et al. Prevalence of COPD in seven areas of Spain. Geographic Variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000;118:981-9.
2. Alonso I, Regidor E, Rodríguez C, Gutiérrez-Fisac JL. Principales causas de muerte en España, 1992. Med Clin (Barc) 1996;107:441-5.
3. National Center for Health Statistics. National Health Interview Survey, 1993.
4. Figueras M. Estimación del impacto de las prácticas asistenciales no recomendadas en el abordaje de la EPOC. Boehringer Ingelheim. Soikos SL. Barcelona, 1999.
5. Sullivan SD, Ramsey SC, Todd AL, Pharm D. The economic burden in COPD. Chest 2000;117:5S-9S.
6. Soler JJ, Sánchez L, Latorre M, Alamar J, Román P, Perpiña M. Impacto asistencial hospitalario de la EPOC. Peso específico del paciente con EPOC de alto consumo sanitario. Arch Bronconeumol 2001;37:375-81.
7. Prescott E, Lange P, Vestbo J. The Copenhagen City Heart Study Group. Socioeconomic status, lung function and admission to hospital for COPD: Results from the Copenhagen City Heart Study. Eur Respir J 1999;13:1109-14.
8. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: Contents, interobserver agreement, and physiologic correlates of two new indexes. Chest 1984;85:751-8.
9. Ferrer M, Alonso J, Prieto L, Plaza V, Monsó E, Marrades R, et al. Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: The spanish example. Eur Respir J 1996;9:1160-6.
10. Spielberger CD, Gorsuch RL, Lushene E. Manual for the state-trait anxiety inventory (Self Evaluation Questionnaire). Palo Alto, CA: Consulting Psycologis Press (Madrid, TEA, 1988).
11. Jellife DB. Assessment of the nutritional status of the community, no 53. WHO, Ginebra, 1966.
12. Sanchis J, Casan P, Castillo J, González N, Palenciano L, Roca J. Normativa para la práctica de la espirometría forzada. Arch Bronconeumol 1989;25:132-42.
13. Roca J, Sanchis J, Agustí-Vidal A, Segarra F, Navajas D. Rodríguez R, et al. Spirometric reference values for a mediterranean population. Bull Eur Physiopathol Respir 1986;22:217-24.
14. Normativa sabre la gasometría arterial. Grupo de Trabajo de la SEPAR para la práctica de la gasometría arterial. Arch Bronconeumol 1998; 34:142-53.
15. Black LF, Hyatt RE. Maximal respiratory pressures: Normal values and relationship to age and sex. Am Rev Respir Dis 1969;99:696-702.
16. Morales P, Sanchis J, Cordero PJ, Díez JL. Presiones respiratorias estáticas máximas en adultos. Valores de referencia de una población caucasiana mediterránea. Arch Bronconeumol 1997;33:213-9.
17. Butland RJA, Pan J, Gross ER, Woodcook AA, Geddes DM. Two, six, and 12 minute walking tests in respiratory disease. Br Med J 1982;284:1607-8.
18. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998;158:1384-7.
19. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Craford. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-21.
20. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
21. Lanes SF, Lanza LL, Wentworth CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998;158:857-61.
22. Williams C, Crossland L, Finnerty J, Crane J, Holgate S, Pearce N, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998;53:7-13.
23. Taylor DR, Sears MR, Cockcroft DW. The beta agonist controversy. Med Clin North Am 1996;80:719-48.
24. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995;346:201-6.
25. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000;117:156-62.
26. Nelson HS, Berkowitz RB, Tinkelman DA, Emmett AH, Rickard KA, Yancey SW. Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med 1999;159:1556-61.
27. Cazzola M, Di Perna F, Noschese P, Vinciguerra A, Calderano F, Girbino G, et al. Effects of formoterol, salmeterol or oxitropium bromide on the dose-response curves to salbutamol in patients suffering from partially reversible COPD. Eur Respir J 1998;11:1337-41.
28. 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993;8:334-9.
29. Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between beta2-adrenoreceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997;350:995-9.
30. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, et al. Cardiac effects of formoterol and salmeterol en patients suffering from COPD with preexisting cardiac arrhytmias and hypoxemia. Chest 1998;114:411-5.
31. VanNoord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action. Eur Respir J 1996;9:1684-8.
32. Wegener T, Hedenström H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992; 102:535-8.
33. 2 adrenoceptor agonists: Interactions in human contracted bronchi. Eur Respir J 1998;11:583-8.
34. Bittar G, Friedman HS. The arrhytmogenicity of theophyline. A multivariate analysis of clinical determinants. Chest 1991;99:1415-20.
35. Eidelman DH, Sami MH, McGregor M, Cosio MG. Combination of theophylline and salbutamol for arrhytmias in severe COPD. Chest 1987;91:808-12.
36. Conradson TB, Eklundh G, Olofsson B, Pahlm O, Persson G. Cardiac arrythmias in patients with mild-to-moderate obstructive pulmonary disease: Comparison of beta-agonist therapy alone and in combination with a xanthine derivate, enprophylline or theophylline. Chest 1985;88:537-42.
37. Smith RP, Johnson M, Ashley J, Rudkin ST, White RJ. Effect of exercise induced hypoxaemia on myocardial repolarisation in severe chronic obstructive pulmonary disease. Thorax 1998;53:572-6.
38. Biernacki W, Harris J, Scholey. QT dispersion: A risk factor for ventricular cardiac arrhytmias in patients with COPD. Eur Respir J 1996;9:47s.
39. Flick MR, Block AJ. Nocturnal vs diurnal cardiac arrhytmias in patients with chronic obstructive pulmonary disease. Chest 1979;75:8-11.
40. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: A multiple logistic regression analysis. Respiration 2000;67:495-5001.
41. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
42. Siu AL, Reuben DB, Ouslander JG, Osterweil D. Using multidimensional health measures in older persons to identify risk of hospitalization and skilled nursing placement. Quality of Life Res 1993;2:253-61.
43. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997;52: 67-71.
44. Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med 1995;333:1547-53.
45. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159: 158-64.
46. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997;10:417-23.
47. Hamilton AL, Killiam KJ, Summers E, Jones NL. Muscle strength, symptom intensity and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995;152:2021-31.
48. O'Donell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: The role of lung hyperinflation. Am Rev Respir Dis 1993;148:1351-7.
49. O'Donell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1557-65.